Alnylam Pharmaceuticals, Inc.
ALNY · Nasdaq
ALNY · Nasdaq
Alnylam develops and sells RNA interference therapeutics, with commercial revenue led by its TTR franchise and AMVUTTRA for transthyretin-mediated disease. Its customers are patients treated through healthcare providers and the broader specialty-pharmaceutical distribution and reimbursement system. The company generated $3.7 billion of revenue and $0.3 billion of net income in FY2025, versus $2.2 billion of revenue and a $0.3 billion net loss in FY2024. In the second quarter of 2026, global net product revenue was approximately $1.2 billion, up 74% year over year, and quarterly net income was $164.5 million.
Alnylam fell $69.41, or 24.07%, from $288.41 to $219.00 over the period. The decisive move came Thursday, July 30, when shares plunged to $205.48 on 9.84 million shares after second-quarter revenue and earnings missed estimates and management cut its 2026 TTR product-sales guidance. That setback overshadowed record AMVUTTRA sales, 74% year-over-year growth in second-quarter global net product revenue to approximately $1.2 billion, and a return to profitability. The stock stabilized near $205.50 Friday, then recovered 7.2% Monday to $220.33 before giving back $1.33 Tuesday. ETF outflows and broad biotechnology pressure were secondary factors, while no additional company-specific catalyst was reported.
